Home > Insider Trading > Filing (0001209191-15-051663)

Filing Details

Accession Number:: 0001209191-15-051663
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-06-09 20:34:16
Reporting Period:: 2015-03-27

Filing Date:: 2015-06-09
Accepted Time:: 2015-06-09 20:34:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1297184	Amphastar Pharmaceuticals Inc.	AMPH	Pharmaceutical Preparations (2834)	330702205

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1611156	Z. Mary Luo	C/O Amphastar Pharmaceuticals, Inc. 11570 6Th Street Rancho Cucamonga CA 91730	Coo, Chief Scientist, Chairman	Yes	Yes	Yes	No
1611157	Y. Jack Zhang	C/O Amphastar Pharmaceuticals, Inc. 11570 6Th Street Rancho Cucamonga CA 91730	Ceo & Chief Science Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-03-27	20,877	$15.43	911,636	No	4	F	Direct
Common Stock	Acquisiton	2015-06-05	48,980	$12.97	960,616	No	4	M	Direct
Common Stock	Disposition	2015-06-05	44,149	$16.46	916,467	No	4	S	Direct
Common Stock	Acquisiton	2015-06-08	30,066	$12.97	946,533	No	4	M	Direct
Common Stock	Disposition	2015-06-08	27,020	$16.61	919,513	No	4	S	Direct
Common Stock	Acquisiton	2015-06-09	28,324	$12.97	947,837	No	4	M	Direct
Common Stock	Disposition	2015-06-09	25,700	$16.24	922,137	No	4	S	Direct
Common Stock	Disposition	2015-03-27	8,641	$15.43	661,666	No	4	F	Indirect	See footnote
Common Stock	Acquisiton	2015-06-05	50,162	$12.97	711,828	No	4	M	Indirect	See footnote
Common Stock	Disposition	2015-06-05	43,989	$16.47	667,839	No	4	S	Indirect	See footnote
Common Stock	Acquisiton	2015-06-08	30,152	$12.97	697,991	No	4	M	Indirect	See footnote
Common Stock	Disposition	2015-06-08	27,100	$16.61	670,891	No	4	S	Indirect	See footnote
Common Stock	Acquisiton	2015-06-09	28,433	$12.97	699,324	No	4	M	Indirect	See footnote
Common Stock	Disposition	2015-06-09	25,800	$16.12	673,524	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	F	Indirect	See footnote
No	4	M	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	M	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	M	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2015-06-05	48,980	$0.00	48,980	$12.97
Common Stock	Employee Stock Option (right to buy)	Disposition	2015-06-08	30,066	$0.00	30,066	$12.97
Common Stock	Employee Stock Option (right to buy)	Disposition	2015-06-09	28,324	$0.00	28,324	$12.97
Common Stock	Employee Stock Option (right to buy)	Disposition	2015-06-05	50,162	$0.00	50,162	$12.97
Common Stock	Employee Stock Option (right to buy)	Disposition	2015-06-08	30,152	$0.00	30,152	$12.97
Common Stock	Employee Stock Option (right to buy)	Disposition	2015-06-09	28,433	$0.00	28,433	$12.97

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
226,020	2015-09-28	No	4	M	Direct
195,954	2015-09-28	No	4	M	Direct
167,630	2015-09-28	No	4	M	Direct
134,838	2015-09-28	No	4	M	Indirect
104,686	2015-09-28	No	4	M	Indirect
76,253	2015-09-28	No	4	M	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,631,594	Indirect	See footnote
Common Stock	5,000	Indirect	See footnote
Common Stock	200,000	Indirect	See footnote

Footnotes

The reported securities were withheld to satisfy the Reporting Person's tax liability in connection with the vesting of deferred stock units (DSUs).
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the each of the reporting persons on December 16, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.28 to $16.5015, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5), (7), (8) and (9) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.41 to $16.85, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.595, inclusive.
The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.28 to $16.52, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.41 to $16.825, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.595, inclusive.
The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons are the sole owners.
The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
The shares are held of record by a trust for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
Shares subject to the option are fully vested and immediately exercisable.